Send to

Choose Destination
J Hum Genet. 2018 Feb;63(2):157-164. doi: 10.1038/s10038-017-0352-4. Epub 2017 Nov 13.

In vivo genome editing via the HITI method as a tool for gene therapy.

Author information

Institute for Advanced Co-Creation Studies, Osaka University, Suita, Japan.
Graduate School of Engineering Science, Osaka University, Toyonaka, Japan.
Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, USA.
Gene Expression Laboratory, Salk Institute for Biological Studies, La Jolla, USA.


Using genome-editing technologies to correct specific mutations represents a potentially transformative new approach for treating genetic disorders. Despite rapid advances in the field of genome editing, it is still unclear whether the long-standing goal of in vivo targeted transgene integration is feasible. This is primarily because current tools are inefficient. In particular, current technologies are incapable of targeted gene knock-in in non-dividing cells, the major building blocks of adult tissues. This poses a significant barrier for developing therapeutic strategies to treat a broad range of devastating genetic disorders. Recently, our group has developed a unique CRISPR/Cas9-based strategy, termed homology-independent targeted insertion (HITI), which enables targeted gene insertion in non-dividing cells, both in vitro and in vivo. This review will summarize current progress in developing this technology, and discuss the potential impact of HITI-based gene-correction therapies.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center